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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed in its late stages and is associated with high mortality rates. Chemotherapeutic intervention for advanced pancreatic cancer involves treatment regimens with gemcitabine, or a combination chemotherapy regimen including 5-fluorouracil (5-FU) (1, 2) . Gemcitabine and 5-FU are pyrimidine analogs that negatively affect the deoxyribonucleotide pool required for DNA replication, thereby producing an indirect suppression of replicative fork functioning and S-phase stress. Unfortunately, these drugs demonstrate only modest efficacy against PDAC disease progression and are associated with toxic side effects (2) . As such, the development of innovative approaches that increase the effectiveness of these drugs, ideally using lowered doses of gemcitabine and/or 5-FU, would be beneficial to pancreatic cancer patient management due to a better therapeutic index of the drugs in clinical practice.
Recent studies have suggested that suppression of the MCM complex (mini-chromosome maintenance) may provide for a novel means of increasing the effectiveness of chemotherapeutic drugs that slow or inhibit replication fork function (3) (4) (5) . The MCM complex (comprised of Mcm2-7 subunits) is the heterohexameric ATPase core of the replicative helicase that is loaded onto DNA at multiple sites only during G1-phase in a process called licensing, which allows for one round of DNA replication per cycle (6) (7) (8) . Certain MCM complexes are chosen to function as active helicases upon recruitment of Cdc45 to MCM cores, along with the GINS complex, producing what is referred to as a CMG helicase (9) (10) (11) . The active CMGs represent the functional origins of DNA replication and proceed with the forks during elongation (9, (11) (12) (13) .
Mammalian cells load more MCM complexes onto DNA during G1-phase than are required to start and complete S-phase (called dormant origins), and estimates from several studies indicate that cells load ~3-10X the number of MCM complexes than are needed (3, 5, 14) . This excess of MCMs serves as a back-up for cells when they are subjected to replication stresses during Sphase, in particular following exposure to fork-slowing agents (3, 5) . Recovery from such agents requires the excess back-up MCMs that had loaded in G1-phase, since no new MCMs can be loaded in S-phase (3-7, 15, 16) .
Studies have shown that reduction/loss of the back-up complement of MCMs causes human tumor cells to become sensitized to drugs that inhibit replication fork progression.
Depletion of Mcm5 to ~25% of normal levels (effectively removing the back-ups) in U2OS osteosarcoma cells does not adversely affect cell growth on its own, but in combination with aphidicolin (DNA polymerase inhibitor) or hydroxyurea (HU; ribonucleotide reductase inhibitor) proliferation is more impaired than with drugs alone (5). A similar anti-proliferative sensitizing effect was observed when Mcm5 suppression occurred in combination with exposure to camptothecin (topoisomerase inhibitor) (5). Reduction of Mcm2 or Mcm3 to ~5-10% of normal levels in HeLa cells also causes hypersensitivity to aphidicolin and HU in terms of loss of proliferative capacity (3) . Finally, reduction of ORC (origin recognition complex) or Cdc6 proteins, both involved in assembly of MCM complexes onto DNA, also sensitizes U2OS, HeLa, and MDA-MB-231 tumor cells to HU and hydrogen peroxide as assessed by viability and proliferative capacity assays (17).
The studies described above indicate that a full complement of MCM complexes are required for cells to remain viable after exposure to certain drugs that slow or block replication fork progression and thereby cause S-phase stress. Reduction of MCM levels produces hypersensitivity to such drugs, and decreases proliferative capacity of the population. Such findings have important implications for clinical application of this concept to anti-neoplastic therapy. As a prediction, co-suppression of MCM function offers the potential to enhance cytotoxicity and effectiveness of anti-neoplastic compounds that similarly affect replication fork activity, for which many exist in the clinical arsenal. However, with the exception of camptothecin, the drugs used thus far to investigate this chemosensitization concept (aphidicolin and HU) are not indicated for clinical management of human cancer (3, 5) . Gemcitabine and 5-FU are used in clinical management of PDAC and function by indirectly blocking replication fork activity (2) . Given the results of these prior studies, it can be inferred that the effectiveness of gemcitabine and 5-FU against PDAC cell proliferation might also be increased in combination with MCM loss. However, a conclusive demonstration of this remains to be shown.
Using PDAC tumor lines as a model system for questions related to pancreatic cancer treatment efficacy, we show here definitive evidence that co-suppression of excess MCM complexes does indeed chemosensitize PDAC lines to both gemcitabine and 5-FU. We demonstrate that partial loss of MCMs, consistent with loss of the back-up complement of MCMs, noticeably reduces the proliferative capacity of PDAC lines beyond that achieved with gemcitabine or 5-FU alone. Mechanistically, MCM reduction renders the tumor cells less capable of recovering DNA replication activity after exposure to anti-neoplastic drug.
Importantly, non-transformed epithelial cells are not sensitized to similar doses of drug and MCM reduction compared to PDAC cells. We also show that MCM co-suppression causes an increase in the apoptotic index of colorectal cancer cells exposed to oxaliplatin or etoposide, two chemotherapeutic agents that similarly function via replication fork slowing mechanisms and are used in the management of colon cancer and other tumor types (18) . Given that these chemotherapeutic compounds are known to be only modest in anti-tumor activity (e.g., for PDAC therapy) and/or display side effects that limit patient tolerance (1, 2, 18-21), our work provides a proof-of-principle that the development of anti-MCM drugs in the future has the potential to increase the therapeutic index of these existing anti-neoplastic drugs. 
Materials and Methods
Cell culture, transfections, and drugs. Panc1 and SW480 cells (both from ATCC) were cultured less than 8 weeks from frozen stocks for these studies. Colo357 were obtained from Dr.
Said Sebti (Moffitt Cancer Center, Tampa, FL), and cultured less than 8 weeks from frozen stocks. HaCaT cells were were obtained from Dr. Petra Boukamp (University of Heidelberg, Germany), and were cultured less than 8 weeks from frozen stocks for this study. HaCaT were generated and characterized as non-tumorigenic and keratinocyte in derivation (22) . Panc1, Colo357, and HaCaT cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (Hyclone), and SW480 cells were cultured in RPMI medium containing 10% fetal bovine serum. Transfections utilized Dharmafect reagent according to manufacturer methods (Thermo Scientific). For clonogenic and apoptosis assays, cells were seeded at 50% density and transfected the next day (time 0-hr) with 1-3nM of siRNA targeting HsMcm7 or HsMcm4 (siGenome Smartpools, Thermo Scientific), or with non-specific control siRNA (siGenome control, Thermo Scientific). Exposure to siRNA pools occurred for 120 hrs (for clonogenic assays), or for 72 hrs (for SW480 apoptosis assays and Panc1 recovery assays).
Exposure to drugs occurred concurrent with siRNA treatment from 72-120 hrs (for clonogenic assays) or 24-72 hrs (SW480 apoptosis assays). Aphidicolin, gemcitabine, 5-fluorouracil, oxaliplatin, and etoposide were purchased from Sigma-Aldrich and used at concentrations indicated.
Immunoblotting and antibodies. For verifying successful siRNA knockdowns of MCM proteins by immunoblotting, equal numbers of cells were lysed and boiled in 1X Laemmli loading dye and analyzed by standard immunoblotting techniques (14) . Chromatin enrichment of samples was done by isolating Triton X-100 detergent-resistant nuclear fractions as described (14, 23) comparisons. Cells were exposed to 100nM gemcitabine for 6 hrs, and medium was changed (at time 0) to remove drug and siRNAs. Cultures were pulsed 30 minutes in duplicate or triplicate with 3µCi/mL tritiated-thymidine at the times indicated. Trichloroacetic acid (TCA) precipitable material was processed for scintillation counting as described (24) . The average counts per minute (cpm) were determined and plotted to measure DNA replication rates for each condition and time after drug removal. indicates that we have significantly suppressed the levels of back-up MCM complexes in Panc1 cells using our conditions. This 1-100nM concentration of siRNA treatment was used throughout our experimental approaches to achieve similar partial reductions of MCM subunit expression across cell types.
Reduction of a single MCM subunit in mammalian cells by siRNA-mediated approaches causes suppression of functional MCM complexes due to the hexameric dependency of the MCM complex for helicase activity (3, 5, 9, 11) . Cells also appear to have a sensing mechanism that maintains equal MCM subunit stoichiometry (3, 14, 28, 29) . This is evident in Panc1 cells, were transferred to dishes at a lower density. At 72 hrs, cells were exposed to various levels of drugs for 2 days, then allowed to culture for the remainder of two weeks. Cells were then fixed, stained, and assessed for resulting colony numbers under each condition. We verified by immunoblotting that the siRNA was effective against Mcm7 during the entirety of the drug exposure from 72 hrs to 120 hrs ( Figure 1D ).
To relate our work to previously published studies (3, 5) , sensitization of Panc1 cells to aphidicolin by Mcm7 suppression was determined. As can be seen in Figure 1E Despite a lack of observable biochemical indicators for replication fork stress, we reasoned that PDAC cells were having difficulty recovering DNA replication after gemcitabine exposure under conditions of reduced MCM levels. This is because back-up MCMs have been shown by single-fiber DNA strand analyses to be required for dormant origin activation during replicative stress (3, 5) . An experiment was designed as shown in Figure 4A Figure 4E ) caused a significant suppression in DNA replication at each time interval relative to untreated and si-control treated samples. Interestingly, although overall amounts of DNA replication were reduced by MCM loss, the slope of the curves were generally similar, indicating that existing forks were likely progressing at similar rates, but that there were fewer overall forks in the cells. This is consistent with the observation that MCM loss blocks activation of dormant origins on DNA fiber analysis (3, 5) . We conclude that PDAC cells exposed to gemcitabine have a diminished ability to recover efficient DNA replication under conditions of MCM suppression. MCM loss and gemcitabine exposure. We next determined if PDAC cells were more sensitive to gemcitabine exposure and MCM reduction relative to non-transformed cells. The immortalized and non-tumor derived cell line HaCaT was used in this analysis (22, 32, 33) . We wanted to compare PDAC cells to this highly proliferative, non-tumorigenic epithelial cell type for two reasons. First, this removed any bias due to slow-proliferating issues (such as with primary cells) that might render drug + MCM loss ineffective simply due to lack of cell cycling/proliferation. Second, chemotherapy tends to cause adverse effects especially on epithelial cells in patients, and HaCaT are keratinocytes in derivation (22) . Clonogenic assays were performed in the same manner as in Figure 1 
Non-transformed epithelial cells and PDAC cells display differential sensitivity to
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Discussion
We provide here definitive evidence that reduction of the excess back-up complement of targeting MCM functionality have the potential to enhance the therapeutic efficacy of current drugs used in PDAC regimens. Colon cancer management often involves the use of oxaliplatin in chemotherapy. However, oxaliplatin is associated with neuropathy that limits the ability to treat patients with this compound (18, 19) . Similarly, etoposide is indicated for use in the clinic against several cancer types, including breast cancer, but etoposide is known to produce cardiotoxic side effects many years after clinical exposure that limit its utility (20, 21) . Our work suggests that the development and use of anti-MCM drugs has the propensity to increase the therapeutic index of these and similar chemotherapeutic compounds when used in combination regimens. This might also allow for a reduced administration of oxaliplatin or etoposide that could mitigate the toxic side effects associated with these drugs. Although the potential utility in suppressing MCM function is clear, an important problem must be considered in any clinical approach targeting MCM suppression over sustained time periods. Partial suppression of MCM function can result in reduced genomic stability and increased DNA damage (3, 5, 28, 31) , and mice with sustained, partially defective MCM function display increased cancer risk (30) 
